News
Ascentage Pharma Announces a New Drug Application for Its Novel Bcl-2 Inhibitor Lisaftoclax Accepted and Recommended Priority Review Designation by CDE of China NMPA
ROCKVILLE, Md. and SUZHOU, China, Nov. 17, 2024 /PRNewswire/ -- Ascentage Pharma (6855.HK), a global biopharmaceutical company engaged in discovering, developing and commercializing therapies to address global unmet medical needs primarily for malign
By: prnewswire_apac
- Nov 18 2024
- 0
- 0 Views
ONLY AVAILABLE IN PAID PLANS